![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 50, 39754-39761, December 15, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
§,
,
From the
Laboratory of Chemical Biology, NIDDK, National
Institutes of Health, Bethesda, Maryland 20892-1822 and the
¶ Pharmacology Group, School of Pharmacy, University of Lausanne,
1015 Lausanne, Switzerland
Received for publication, June 8, 2000, and in revised form, September 1, 2000
| |
ABSTRACT |
|---|
|
|
|---|
Erythropoietin (Epo) is required for the
production of mature red blood cells. The requirement for Epo and its
receptor (EpoR) for normal heart development and the response of
vascular endothelium and cells of neural origin to Epo provide evidence
that the function of Epo as a growth factor or cytokine to protect
cells from apoptosis extends beyond the hematopoietic lineage. We
now report that the EpoR is expressed on myoblasts and can mediate a
biological response of these cells to treatment with Epo. Primary
murine satellite cells and myoblast C2C12 cells, both of which express
endogenous EpoR, exhibit a proliferative response to Epo and a marked
decrease in terminal differentiation to form myotubes. We also observed that Epo stimulation activates Jak2/Stat5 signal transduction and
increases cytoplasmic calcium, which is dependent on tyrosine phosphorylation. In erythroid progenitor cells, Epo stimulates induction of transcription factor GATA-1 and EpoR; in C2C12 cells, GATA-3 and EpoR expression are induced. The decrease in differentiation of C2C12 cells is concomitant with an increase in Myf-5 and MyoD expression and inhibition of myogenin induction during differentiation, altering the pattern of expression of the MyoD family of transcription factors during muscle differentiation. These data suggest that, rather
than acting in an instructive or specific mode for differentiation, Epo
can stimulate proliferation of myoblasts to expand the progenitor population during differentiation and may have a potential role in
muscle development or repair.
Erythropoietin (Epo)1 is
required for the development and maturation of erythroid cells and acts
to stimulate the proliferation and differentiation of erythroid
progenitor cells. Mice lacking expression of erythropoietin or its
receptor die in utero due to insufficient erythropoiesis in
the fetal liver (1). Erythropoietin production can be induced by
hypoxia and provides physiologic regulation of the red cell mass.
Erythropoietin receptor is a member of the cytokine receptor
superfamily characterized by a single transmembrane domain, homology in
the extracellular domain that includes a WSXWS motif, and a
cytoplasmic domain that does not contain a kinase motif. Binding of
erythropoietin to its receptor results in receptor dimerization,
increased affinity for Jak2 to the receptor's membrane proximal
region, and subsequent phosphorylation of Jak2 and tyrosines on the
cytoplasmic region of the receptor (2). As with other members of this
superfamily such as thrombopoietin, interleukin-3,
granulocyte-macrophage colony-stimulating factor, and prolactin, Jak2
is required for signaling (3, 4) and Jak2 phosphorylation activates
Stat5 (5, 6) and other signal transduction pathways. A role for calcium
has been implicated in erythropoietin activity. For example, in
erythroid progenitor cells, erythropoietin activates an increase
in intracellular calcium in a dose-dependent manner
mediated via tyrosine phosphorylation of the erythropoietin receptor
requiring the cytoplasmic tyrosine 460 (7). The ability of prolactin
with retrovirally induced prolactin receptor expression to rescue
late stages of erythropoiesis (8) suggests that the primary function of
erythropoietin may be its activity as a viability (9, 10) and
proliferation factor (11) secondary to its ability to induce erythroid differentiation.
Expression of erythropoietin receptor is not restricted to the
erythroid lineage and can be found on hematopoietic stem cells (12),
and cells of endothelial (13, 14) and neural origin (15). In select
endothelium such as the chick embryo chorioallantoic membrane and mouse
uterine endometrium, erythropoietin administration in vivo
can stimulate neovascularization or blood vessel formation (14, 16). In
vascular smooth muscle cells, Epo can stimulate calcium influx and act
as a vascular growth factor (17). Erythropoietin production is
inducible by hypoxia, and in vivo results in increased erythropoiesis. In neuronal cells, erythropoietin provides protection from oxidative stress in culture (18), and protects neurons from
ischemic damage in vivo (15). Erythropoietin is also
expressed in the embryonic heart. Recent observations reveal a defect
in non-hematopoietic development related to
erythropoietin/erythropoietin receptor. Mice lacking erythropoietin or
erythropoietin receptor expression suffer from ventricular
hypoplasia and exhibit a reduction in the number of proliferating
cardiac myocytes (19).
We now report on the expression of EpoR on primary satellite cells
isolated from skeletal muscle and on myoblast C2C12 cells, although
EpoR expression was not previously detected on analysis of whole
skeletal muscle (20, 21). Stimulation with Epo enhances proliferation,
and reduces differentiation and fusion of these cells into myotubes.
During differentiation Epo stimulation affects the production of the
MyoD transcription factors, increases the expression of MyoD,
associated with a less differentiated state, and suppresses or delays
the increase expression of myogenin, usually expressed at high levels
in myotubes. Myoblasts, but not myotubes, respond to Epo with an
increase in cytoplasmic calcium. The expression of EpoR on myoblasts
and their response to Epo support the hypotheses that the role of EpoR
extends beyond erythropoiesis and that Epo and EpoR play a role in the
proliferation and differentiation of muscle cells.
Generation of Transgenic Mice--
Human EpoR proximal promoter
fragments extending 5' up to Cell Culture and Reagents--
The human erythroid OCIM1 cell
line was maintained in Immunoprecipitation and Western Blotting--
Cells (2 × 106) were cultured in serum-free medium for 16 h.
Cells were treated with tyrphostin A51 (Anawa, Switzerland) for 5 min
as indicated, then exposed to 5 units/ml Epo for 30 min. For whole cell
extracts, cells were twice washed with cold PBS and then treated with
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, and
protease inhibitors). For immunoprecipitation, 1 mg of whole cell
extract was incubated with 1 µl of mouse EpoR anti-rabbit polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or 4 µg of
anti-phosphotyrosine 4G10 antibody (Upstate Biotechnology, Lake Placid,
NY) overnight at 4 °C. Protein A agarose-captured immunocomplexes
were separated on a 4-12% Novex Bis-Tris NuPAGE gel by
electrophoresis (Invitrogen, Carlsbad, CA) and transferred to
polyvinylidene difluoride membrane (Invitrogen, Carlsbad, CA) using
Novex Xcell II Mini-Cell and Blot Module (Invitrogen, Carlsbad, CA).
Membranes were probed with 1:1000 dilution of EpoR rabbit polyclonal
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 1 µg/ml
anti-phosphotyrosine 4G10 antibodies, anti-Jak2 (1:1000), and 1 µg/ml
anti-STAT5A (Upstate Biotechnology, Lake Placid, NY) followed by
horseradish peroxidase-coupled secondary antibodies and developed by
ECL (Amersham Pharmacia Biotech, Piscataway, NJ).
Immunofluorescence--
Cells grown on collagen-coated slides
(Biocoat, Becton Dickinson, Bedford, MA) were fixed for 1 h in 4%
paraformaldehyde, then rinsed twice for 10 min with 1× PBS. Cultures
were then blocked with 10% normal serum (rabbit or goat) in PBS for 30 min at room temperature. The cells were then incubated with primary
antibody (EpoR or MF-20) for 2 h in 1.5% normal serum and washed
three times in PBS. The primary antibodies EpoR (Santa Cruz
Laboratories, Santa Cruz, CA) or MF-20 hybridoma specific for myosin
heavy chain (26) were diluted 1:2000 and 1:4, respectively.
Fluorescein-labeled anti-mouse and rhodamine-labeled anti-mouse for
EpoR and MF-20, respectively, were used as secondary antibodies.
mRNA Analysis--
Messenger RNA was extracted and purified
from myoblasts at indicated time points using an oligo(dT)-cellulose
spin column (Amersham Pharmacia Biotech) and used for Northern blot
analysis. For RT-PCR, reverse transcription of isolated mRNA and
amplification of cDNA were performed using Superscript IITM
reverse transcriptase (RT) (Life Technologies, Inc.). 60 ng of mRNA
were incubated with RT for 1 h at 42 °C. PCR was used to assess
expression of EpoR, GATA-3, Myf-5, myogenin, and S16. Amplification was
carried out under the following conditions: 20 mM Tris, pH
8.3, 50 mM KCl, 2.0 mM MgCl2, 0.2 mM dNTPs, 0.2 mM specific upstream and
downstream primers (Table I), 5% RT
reaction mix, and 5 units/ml Taq DNA polymerase (Promega,
Madison, WI). The PCR cycles were 94 °C for 5 min for 1 cycle,
94 °C for 1 min, 54°-68 °C (template-dependent) for
2 min, 72 °C for 3 min for 35 cycles, followed by a 7-min elongation
at 72 °C.
Quantitative Real-time RT-PCR--
Quantitative real-time PCR
assay was carried out with the use of gene-specific primers (Table
II) and fluorescently labeled TaqMan
probes or SYBR Green dye (Molecular Probes, Inc., Eugene, OR) in a 7700 Sequence Detector (PE Applied Biosystems, Foster City, CA). The TaqMan
probe is designed to span exon junctions in order to prevent the
amplification of any contaminating genomic DNA. Specific probes were
used for EpoR, GATA-3, and S16 (Table III). Plasmid containing the cDNA of
interest was used as template to generate a standard curve. S16 was
used as an internal control.
Measurements of the Cytosolic Calcium
Concentration--
Cytosolic calcium concentration
([Ca2+]c) measurements were
performed on 2-4-day-old myoblasts or 7-9-day-old myotubes loaded
with the fluorescent dye Fura-2. Cells grown on gelatin-coated glass
coverslips were washed three times with control physiological salt
solution (PSS; composition, in mM: NaCl 145, KCl 5, MgCl2 1, HEPES 5, glucose 10 and CaCl2 1.2, pH
7.4 at 37 °C). Cells were incubated in the dark for 45 min at room
temperature with Fura-2/AM (5 µM) (Molecular Probes Inc.,
Eugene, OR) in PSS buffer containing 0.01% Pluronic F-127 (Molecular
Probes Inc.) and 0.1% Me2SO. Cells grown on coverslips
were washed six times with PSS, transferred to a superfusion chamber
thermostated at 37 °C, and superfused with PSS buffer. The chamber
was mounted onto the stage of an inverted epifluorescence microscope
(Nikon Diaphot, Tokyo, Japan). The cells were excited at alternating
wavelengths of 340 and 380 nm with a rotating filterwheel, and emission
was monitored at 510 nm with a PhoCal cell fluorescence analyzer (Life
Science Resources, Cambridge, United Kingdom). The ratio R
of the emitted light (510 nm) at 340 and 380 was determined and
calibration was performed by treating the cells with CaCl2
(6 mM) and ionomycin (10 µM) to obtain
Rmax, followed by the addition of EGTA (40 mM) to estimate Rmin. Background
fluorescence, obtained by quenching the fluorescence with
MnCl2 (10 mM), was subtracted from all
measurements. Results are given as
[Ca2+]c calculated as described
(27). Cells were stimulated by Epo (Amgen Inc., Thousands Oaks, CA),
carbachol (carbamoylcholine chloride, Fluka, Switzerland), tyrphostin
A51, or incubated in absence of extracellular calcium (buffer
composition, in mM: NaCl 145, KCl 5, MgCl2 1, HEPES 5, and EGTA 3, pH 7.4 at 37 °C).
EpoR Expression in Myoblasts--
Transgenic mice produced from
the lacZ reporter gene driven by the human EpoR promoter
(21) provided evidence that EpoR may be expressed in muscle progenitor
cells or developing muscle (Fig. 1).
Transgene expression was observed in fetal liver, the site of fetal
hematopoiesis. Other sites of transgene expression included regions
associated with developing muscle and expression of MyoD and/or Myf-5
such as the visceral arches, the proximal forelimb, and intercostal
area. The facial and forelimb staining pattern were observed in embryos
constructed from a promoter fragment as short as
Examinations of isolated myoblasts show that they also express EpoR and
are responsive to Epo stimulation. The murine C2C12 myoblast cell line
(23, 24) can be maintained in a proliferating state by culture in
growth medium (containing 10% serum) and can be induced to
differentiate and fuse into myotubes in differentiation medium
(containing 2% serum). To examine EpoR expression in C2C12 cells, RNA
was isolated and the presence of EpoR transcripts determined by
Northern blot analysis. A specific 32P-labeled probe was
prepared by random labeling of a full-length 1.7-kilobase pair murine
EpoR cDNA fragment. This probe showed specific hybridization with
mRNA isolated from C2C12 cells corresponding to an EpoR transcript
similar in size to that detected in the control RNA from erythroid
cells (Fig. 2A). Satellite
cells, muscle progenitor cells, make up only a small fraction of 2 to
7% of the total population (28) of the adult skeletal muscle and
exhibit the potential for repair and maintenance of skeletal muscle
(29). To directly determine the expression of EpoR on these muscle
progenitor cells, primary satellite cells were isolated from adult
mouse skeletal muscle and cultured in vitro. These primary
cells were analyzed within five passages. RNA was isolated and used for
RT-PCR analysis (Fig. 2B). Expression of EpoR transcripts
was readily detected in the satellite cell cultures using specific
primer pairs (Table I). The presence of Myf-5, an early MyoD
transcription factor, was used to confirm the cell type of these less
differentiated myocytes. As a positive control, primers specific for
mouse S16 protein were used. The low number of satellite cells or
myoblasts in adult skeletal muscle would account for the lack of EpoR
detection in our earlier studies of adult skeletal muscle (21).
For analysis of EpoR protein, whole cell extracts were prepared from
C2C12 cells and primary satellite cell cultures. Western blot analysis
showed specific binding of antibodies directed against the mouse EpoR
to a band corresponding to the size of the EpoR control (Fig.
2C), confirming that the EpoR transcripts are functional and
translated into EpoR protein. For immunohistochemistry, myoblast cells
were cultured in growth medium on collagen-coated slides and harvested
for staining (Fig. 2D). The mouse EpoR antibody was used as
primary antibody followed by fluorescein-conjugated secondary antibody.
Staining of C2C12 cells and of primary satellite cells confirmed the
production of EpoR protein in these cells. The antibody staining was
specific and could be blocked by specific EpoR polypeptide.
Epo Stimulation of Myoblast Proliferation--
Myoblasts
expressing EpoR exhibited a mitogenic response to Epo. When Epo was
added to the growth medium, enhancement of proliferation was observed
(Fig. 3). The proliferative effect of Epo
was even more apparent in differentiation medium (Fig. 3, B
and D). These cultures reached confluence 48 h or more
before the untreated C2C12 cells. In the absence of serum, cell death
occurred within 48 h. Epo could postpone but not prevent cell
death. Epo concentrations up to 100 units/ml were added to C2C12
cultures, and the proliferative effect of Epo on myoblasts was
dose-dependent (Fig. 3, A and B). The
optimum Epo concentration for proliferation was at 1 unit/ml for cells
cultured in growth medium and in differentiation medium, a
concentration used to culture primary erythroid progenitor cells (30).
These results indicate that Epo induces a proliferative response in
C2C12 myoblasts cultured under either growth or differentiation conditions.
Primary satellite cells harvested from adult mouse skeletal muscle were
also responsive to Epo and exhibited a marked effect on proliferation
and differentiation. As with C2C12 myoblasts, addition of Epo to the
culture medium increased proliferation of the satellite cells and
extended the ability to passage these cells. As observed for C2C12
cells, the effect on proliferation was more pronounced when the cells
were cultured in differentiation medium (Fig. 3E), where
proliferation without Epo stimulation was markedly reduced.
Inhibition of Myoblast Differentiation--
Proliferating C2C12
myoblasts continue to grow and divide when reseeded in growth medium
(Fig. 4A). In contrast, after
48-72 h in differentiation medium, the cells will begin to fuse giving rise to multinucleated cells, leading to myotube formation (Fig. 4G) and loss of proliferative capacity. When Epo was added
at 1 unit/ml to cells cultured in growth medium, no change in cell morphology was observed (Fig. 4B). C2C12 cells cultured in
differentiation medium with Epo retained their proliferative capacity
and differentiated myotubes was reduced or delayed (Fig. 4,
E and H). These cells could be reseeded
indefinitely in differentiation medium in the presence of Epo. However,
these cells retained their ability to differentiate when cultured in
medium without Epo. When cells were exposed to Epo in growth medium and
then cultured in differentiation medium without Epo, terminal
differentiation and myotube formation was observed analogous to cells
receiving no prior exposure to Epo. The ability of Epo to inhibit
differentiation required exposure to Epo up to 24 h prior to
culture in differentiation medium and appeared to require the continued
presence of Epo. Without preincubation with Epo in growth medium, no
effect on differentiation and myotube formation was observed with Epo
addition to differentiation medium. The specificity of Epo to inhibit
differentiation of these myoblasts was confirmed by the addition to the
culture medium of polyclonal antibody (gift of Alan D'Andrea) directed
against the extracellular domain of the murine EpoR (Fig. 4,
C, F, and I). Epo antibody directed to
the cytoplasmic domain did not appear to be effective. When added
together with Epo, the anti-EpoR antibody appeared to neutralize the
ability of Epo to interfere with differentiation and reduce myotube
formation in these cultures (Fig. 4I), comparable to culture
conditions with the absence of Epo. These results confirm that Epo
blocks differentiation of C2C12 myoblasts through interactions with its
receptor. The inhibition of differentiation by Epo was also observed in
primary satellite cell cultures.
Antibody specific for myosin heavy chain (MF-20) was used to identify
the differentiated myocyte or myotube. C2C12 cells were grown in
differentiation medium without Epo (Fig. 4J) were compared with cells grown in the presence of Epo (Fig. 4K). C2C12
myoblasts that were allowed to differentiate exhibited positive
staining with the MF-20 antibody (Fig. 4L), while cells
cultured in the presence of Epo did not stain with the MF-20 antibody
(Fig. 4M). Differentiation of primary satellite cells was
also confirmed by staining with the MF-20 antibody, and staining with
the MF-20 antibody was not observed when satellite cells were cultured
in differentiation media with Epo.
Increase of Intracellular Calcium by Epo--
Epo stimulation of
erythroblasts has been shown to stimulate an increase in their
cytosolic calcium concentration
[Ca2+]c (31). We found that C2C12
cells at their myoblast stage responded also to Epo stimulation by
increasing [Ca2+]c (Fig.
5). C2C12 cells grown on coverslips were
loaded with Fura-2, and changes in fluorescence ratios (340/380 nm
excitation), indicative of
[Ca2+]c, were monitored. The
Ca2+ transients of myoblasts and of fused and
differentiated myotubes were compared after exposure to Epo and
carbachol, an analogue of acetylcholine known to stimulate
[Ca2+]c elevations via activation
of the nicotinic acetylcholine receptor. Addition of 10 units/ml Epo
caused an immediate increase in
[Ca2+]c in myoblasts (Fig.
5A). As this response was abolished when incubating the
cells for 1 min with EGTA (Fig. 5C), it was entirely
dependent on the presence of extracellular Ca2+, indicating
stimulation by Epo of a Ca2+ influx pathway. In contrast,
fused myotubes of C2C12 cells did not respond to Epo. However, they
responded to carbachol (100 µM, CCh) with a rapid
increase in [Ca2+]c, which was
similar in magnitude to the one caused by Epo (Fig. 5B),
demonstrating that the differentiated myotubes were able to respond to
a well known stimulus. Carbachol, however, had no effect on
undifferentiated myoblasts (Fig. 5A). As the erythropoietin
receptor is known to signal via tyrosine kinase pathways, we examined
whether an inhibitor of tyrosine kinase (32) affected the calcium
response to Epo in myoblasts. The calcium increase elicited by Epo was
completely inhibited by tyrphostin A51 (10 µM) in 50% of
the cells and to a very large extent in remaining cells (Fig.
5D).
Stimulation of Phosphorylation by Epo--
Treatment of C2C12
cells with Epo resulted in tyrosine phosphorylation of Jak2 and Stat5
in response to Epo. In erythroid progenitor cells, Epo binding to its
receptor activates Jak2/Stat5 as well as other signal transduction
pathways, and Jak2 plays a critical role in cellular response to Epo
(3, 4). Cellular extracts were isolated from C2C12 cells treated with
and without Epo. Extracts were immunoprecipitated with an
anti-phosphotyrosine antibody and Western-blotted with anti-Jak2 or
anti-Stat5 antibody (Fig. 6). Bands
corresponding to the molecular mass of Jak2 (130 kDa) and Stat5 (95 kDa) suggested increases in Jak2 and Stat5 phosphorylation upon Epo
stimulation. Phosphorylation of these proteins was blocked in a
concentration-dependent manner by tyrphostin A51, an
inhibitor of tyrosine kinases. In contrast, no change in
phosphorylation of Jak3 was observed (data not shown).
Modulation of MyoD Transcription Factor Family Expression by
Epo--
During myogenesis there is a sequential induction of the MyoD
basic helix-loop-helix family of transcription factors that bind E-box
motifs (CANNTG) with expression of Myf-5 and MyoD in early myoblasts,
followed by expression of myogenin and loss of Myf-5 in the
differentiated muscle cell. C2C12 cells were cultured with and without
Epo under proliferative and differentiation-permissive conditions and
mRNA isolated to determine the expression pattern of these
transcription factors (Fig.
7A). RT-PCR analysis was carried out using primers specific for Myf-5, MyoD, and myogenin (Table
I). Amplification with primers specific for S16 was used as control for
the amount of mRNA used. In the absence of Epo, Myf-5 expression
was observed only in undifferentiated C2C12 cells cultured in growth
medium or during early exposure to differentiation medium. In the
presence of Epo, Myf-5 expression persisted in differentiation medium.
The levels of MyoD appeared to be induced earlier in the presence of
Epo compared with levels observed in myoblasts grown without Epo in
differentiation media. Differentiation of myoblasts into myotubes
resulted in a marked induction of myogenin, whereas a more modest or
delayed increase in myogenin was observed in cells cultured with Epo.
These results suggest that Epo is able to alter the programmed
expression of the MyoD transcription family members usually associated
with induction of differentiation. The EpoR proximal promoter contains
binding sites for transcription regulators Sp1 and the largely
erythroid GATA-1 that are critical for transcription control in
erythroid cells (33, 34). In the development of the erythroid lineage,
the transcription factor, GATA-1, and EpoR are closely linked and
GATA-1 can transactivate the EpoR promoter. In myoblasts, we observed
expression of another member of the GATA-like transcription factor
family, GATA-3. In addition to altering expression of the MyoD
transcription factor family members, stimulation of myoblast C2C12
cells by Epo induced the expression of GATA-3.
The induction of EpoR and MyoD transcription factors by Epo was
confirmed by real-time quantitative RT-PCR (Fig. 7, B-G). C2C12 cells cultured in the presence of Epo showed an increase of about
6-fold in EpoR, 3-fold in Myf-5, 1.5-fold in MyoD, and 2-fold in
GATA-3. The induction of myogenin after 2 days of culture in
differentiation media was about 80-fold in the absence of Epo (Fig.
7F). In the presence of Epo, the induction of myogenin in differentiation media was 2.4-fold lower than in the absence of Epo.
Epo also altered the expression of the MyoD transcription factor family
in satellite cells (Fig. 7G). Note that, as C2C12 cells
cultured in growth medium approached confluence (4-5 days), we
observed an increase in myogenin expression but significantly lower
than that observed in differentiating C2C12 cells. When these cells
were reseeded at low density, myogenin levels dropped to base-line
values. The increase in myogenin levels in the presence of Epo detected
for C2C12 cells in growth medium cultured for 3 days (Fig.
7F) was comparable to levels in control cultures observed
24-48 h later. This likely reflects the increase in proliferation of
C2C12 cells by Epo and the shorter time required for the cells to
become confluent. Quantitation of mRNA from satellite cells cultured in differentiation media for 2 days with Epo showed a 1.4-fold
increase in EpoR and Myf-5 expression. The most dramatic change was
observed for MyoD, which exhibited a 10.5-fold increase in the presence
of Epo. The induction of myogenin was lower by a factor of 0.57 compared with the level observed in the absence of Epo.
Epo is known for its role in hematopoiesis in the stimulation of
proliferation and differentiation of erythroid progenitor cells (35).
The data presented here and other investigations into the tissue
distribution of EpoR indicate that it is not restricted to the
erythroid lineage. Epo response has been identified on cells of
endothelial and neuronal origin in vitro (36, 37), and
in vivo in neovascularization and uterine angiogenesis (14, 16) and in protecting neurons from ischemic damage (15). This current study demonstrates that EpoR is also expressed on C2C12 myoblasts and primary satellite cells and functions, upon Epo stimulation, to maintain a proliferative state and suppress
differentiation. These observations suggest that Epo may participate in
muscle development or repair. We found that myoblasts express EpoR and exhibit a dose-dependent growth response to Epo capable of
reducing differentiation to myotubes. This activity of Epo is another
example of the interplay between growth and differentiation in the
control of myogenesis (40, 41). The survival effect of Epo was most striking on primary satellite cells in which no growth was observed in
low serum in the absence of Epo. Maturation to myotubes results in a
down-regulation of EpoR, and EpoR is not detectable in mature myotubes
or adult skeletal muscle, consistent with the relatively low number of
satellite cells present in the total population (28). The
down-regulation of EpoR expression during differentiation/maturation is
analogous to that observed during erythropoiesis and EpoR is not
expressed on mature red blood cells. It is likely that this down-regulation in myoblasts is a secondary event to
differentiation/maturation.
Culture of myoblasts under differentiating conditions with Epo results
in an increase in EpoR expression accompanying cell proliferation, as
also observed for Epo-stimulated differentiating erythroid progenitor
cells (42). The existence of EpoR on myoblasts and other non-erythroid
cells leads us to postulate a more general role for Epo: to
maintain/expand the pool of proliferating progenitor cells during
differentiation, not only for hematopoietic tissue, but in other
tissues such as during muscle maintenance or repair, or muscle
development. Currently there are two hypotheses to explain the role of
growth factors in proliferation and differentiation. In the first, a
stochastic model, differentiation of stem cells along specific lineages
proceeds in a predetermined fashion. The role of growth factors in this
model is to provide, through enabling survival and enhancing
proliferation, a sufficient pool of progenitors (43). On the other
hand, the instructive model gives growth factors a direct role in the
determination of cell fate (44). Studies in erythroid progenitor cells
show that an overexpressed prolactin receptor stimulated by prolactin
supported proliferation of erythroid progenitors, which could then
differentiate appropriately supporting the stochastic model (8, 45).
The presence of EpoR on myoblasts and their proliferative response with
reduced differentiation provides further evidence for a stochastic role for Epo and its receptor, rather than Epo activating genes specifically related to erythroid differentiation and maturation, i.e.
Epo acts as a survival factor to stimulate proliferation and inhibit apoptosis rather than as a specific growth factor that activates the
erythroid program. Similar trophic effects in B lymphocytes (47), fetal
liver stromal cells (48), endothelial cells (36), neuronal cells (49),
and cardiomyocytes (50) support this hypothesis. These results suggest
that the cellular response to Epo is more general and may be related to
stress response or tissue development.
Epo stimulation is associated with activation of the Jak2/Stat5 (4) and
other signal transduction pathways, as well as a rapid calcium influx
in human erythroblasts (51). Epo binding in hematopoietic cells induces
tyrosine phosphorylation of several proteins including EpoR itself and
possibly calcium channel proteins (31, 52). Epo has also been shown to
cause a Ca2+ influx in the neuronal cell line (PC12) and
vascular endothelial cells (37, 53). Similarly, our results show that
Epo stimulation caused a significant increase in
[Ca2+]c in myoblasts, most likely
resulting from an influx. Since Epo stimulates Jak2/Stat5 and other
signal transduction pathways, the inhibition of
[Ca2+]c increase by tyrphostin
A51, a tyrosine kinase inhibitor, suggests that modulation of influx is
downstream of the initial signaling events and requires activation of
one or more signal transduction pathways. These results support
previous observations that tyrosine phosphorylation has a functional
role in regulation of calcium channels by Epo, suggesting that this is
may be a key mechanism for Epo modulation of gene expression. Previous
studies on differentiated cardiomyocytes were unable to show an
increase of Ca2+ influx when cardiomyocytes were treated
with physiological levels of Epo (54). This observation is consistent
with our findings that in contrast to myoblasts, differentiated
myotubes did not display an influx of Ca2+ in response to
Epo. Although EpoR ( Myogenic basic helix-loop-helix proteins such as MyoD, Myf-5, and
myogenin are required for myogenesis (55). Myogenesis is realized by
the binding of these factors to E-boxes (CANNTG) in the control regions
of other myogenic transcription factors (56). Myf-5 and MyoD are
expressed in early and mid-myogenesis. As the cells progress toward the
differentiated phenotype, myogenin is expressed late in the myogenesis
pathway and, once present in high levels, signals irreversible
commitment to terminal differentiation (57). Epo stimulation affects
the expression pattern of muscle-specific transcription factors, but
the effect of Epo on C2C12 cells and primary satellite cells is
transient, as observed in interruption of myogenesis by other select
growth factors such as fibroblast growth factor and transforming growth
factor type Satellite cells located below the basal lamina of adult skeletal muscle
comprise only a small proportion (2-7%) of the nuclei associated with
a muscle fiber (28, 59) depending on age and muscle type. Although
ordinarily inactive, they and their descendants have a very large
potential for proliferation and exist throughout adulthood as a
potential source of new myoblasts. Satellite cells become activated
when muscle is injured or diseased, and will divide and differentiate
into myoblasts and fuse to existing, damaged muscle fibers or form new
ones (60). Epo, produced primarily in the kidney and secreted into the
circulation, is a stress-responsive cytokine. Epo production is highly
inducible by hypoxia. The effect of Epo on satellite cells may play a
role in muscle stress response, particularly to ischemia or hypoxia. We
have also observed that the Epo effect on proliferation of primary
satellite cells is further induced when cultured under hypoxic
conditions (data not shown).
The response of myoblasts to Epo indicates that the role of Epo as a
growth factor is to maintain proliferation and prevent apoptosis (38)
of stimulated progenitor cells during differentiation rather than to
act in an instructive mode. Observations that muscle stem cells
possibly related to the satellite cell population share similarities to
hematopoietic stem cells in that they are able to repopulate to some
extent both muscle and hematopoietic tissue (39, 46) demonstrate a more
general potential of cells in the stem cell compartment than was
previously appreciated. The results reported here suggest that the
similarities may extend further as stem cells differentiate toward
various progenitor cell lineages providing a more general role for
hematopoietic cytokines/growth factors such as Epo in stimulating
proliferation and providing protection from apoptosis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1778 bp and 3' to the ATG start site of
translation were used to drive expression of a lacZ reporter
gene (21). For generation of transgenic mice, the EpoR
promoter/reporter gene construct was excised from plasmid, isolated,
purified, and used for oocyte injection as described previously.
Embryos from established lines were harvested from pregnant mice and
stained for
-galactosidase activity (21). Endogenous EpoR expression
was determined by RT-PCR of RNA isolated from embryonic tissue as
described previously (20, 21).
-minimal essential medium containing 10%
fetal bovine serum (FBS) (22). HeLa cells were cultured in Eagle's
modified essential medium supplemented with 10% FBS. The murine C2C12
myoblast cell line was propagated in Dulbecco's modified Eagle's
medium supplemented with 10% FBS (growth medium) in a humidified
atmosphere of 5% CO2 at 37 °C (23, 24). To induce
differentiation, myoblasts were allowed to grow to approximately 80%
confluence and then switched to differentiation medium (Dulbecco's
modified Eagle's medium with 2% FBS). When Epo was added to the cell
cultures, it was used at a final concentration of 1 unit/ml unless
otherwise indicated. Primary satellite cells were isolated from freshly harvested mouse skeletal muscle as described (25) with the following modification. After dissection and mincing of muscle fragments, tissue
was dissociated using 0.24% trypsin (Life Technologies, Inc.,
Gaithersburg, MD) and 0.1% collagenase (Roche Molecular Biochemicals,
Indianapolis, IN). Cells were cultured in F-10 medium with 20% FBS,
0.5% chick extract (Life Technologies, Inc.), and penicillin/streptomycin (Life Technologies, Inc.). For proliferation assays, 106 C2C12 cells were seeded onto 100-mm plates,
trypsinized at specific time points, diluted, and counted with a
hemocytometer. Epo was added (up to 10 units/ml) as indicated under
"Results." In separate experiments, fetal bovine serum (0-20%)
was added at different concentrations with and without Epo (1 unit/ml).
To assay myogenic differentiation, 1 × 106 cells were
plated on 100-mm dishes in growth medium. 24 h later, the culture
was changed to differentiation medium. Plates were grown in duplicate,
and half received Epo at 1 unit/ml unless otherwise indicated.
PCR primers used for RT-PCR analysis
PCR primers used for real-time quantitative RT-PCR analysis
TaqMan probes used for real-time quantitative RT-PCR analysis
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
150 bp 5', and
expression of the endogenous EpoR in these areas was confirmed by
tissue dissection and RT-PCR.

View larger version (108K):
[in a new window]
Fig. 1.
Transgenic mice containing human EpoR
promoter and 5'-untranslated region linked to the lacZ
reporter gene. A, transgene expression driven by
an EpoR promoter fragment extending to
150 bp 5' was determined at
embryonic day 12.5 with staining in the region of the visceral arches
(open triangle) and base of limbs
(closed triangle). B, facial staining
at day 13. C, In addition to facial staining and staining in
base of limbs, a longer EpoR promoter fragment extending to
1778 bp
5' with a 3' BamHI fragment containing IVS-1 also provided
staining in the intercostal regions (arrow). L
indicates staining in the fetal liver.

View larger version (69K):
[in a new window]
Fig. 2.
Expression analysis of EpoR and transcription
factors in C2C12 and satellite cells. A, For Northern
blot analysis, 1 and 10 µg of mRNA from C2C12 cells were used. A
mouse EpoR-cDNA was randomly labeled with 32P and used
for blot hybridization. Messenger mRNA from the OCIM1
erythroleukemia line was used as control (lane
C). M indicates the marker lane. B,
satellite cells were isolated from mouse leg skeletal muscle and
mRNA was prepared. Expression of Myf-5 (lane
1) and EpoR (lane 2) was determined by
RT-PCR. RT-PCR analysis for S16 mRNA (lane 3)
was used as control. M indicates marker lane. C,
C2C12 cells (lanes 1 and 2), primary
satellite cells (lane 3), and HCD57
erythroleukemia cells included as a control (lane
C) were analyzed by Western blot using anti-EpoR antibody.
Lane 2 contains half the amount of protein used
in lanes 1, 3, and C. D, for immunofluorescent analysis of myoblasts, C2C12 cells
and primary satellite cells were incubated with anti-EpoR antibody
followed by fluorescein-conjugated secondary antibody.

View larger version (27K):
[in a new window]
Fig. 3.
Epo stimulation of myoblast
proliferation. A, cell proliferation was determined for
C2C12 cells cultured in growth medium with Epo ranging from 0 to 10 units/ml. B, cell proliferation was determined for C2C12
cells cultured in differentiation medium with Epo ranging from 0 to 10 units/ml. Epo was used at 0 units/ml (closed
diamonds, dashed line), 0.25 unit/ml
(open squares), 0.5 unit/ml (open
triangles), 1 unit/ml (closed circles,
heavy line), and 10 units/ml (inverted
open triangles). C, cell proliferation
was determined for C2C12 cells cultured in growth medium in the absence
(open diamonds, dashed
line) and presence (closed circles) of
Epo (1 unit/ml). D, cell proliferation was determined for
C2C12 cells cultured in differentiation medium in the absence
(open diamonds, dashed
line) and presence (closed circles) of
Epo (1 unit/ml). E, the proliferative effect of Epo on
isolated primary satellite cells was observed when cells were cultured
in differentiation medium in the absence (open
diamonds, dashed line) and presence
(closed circles) of Epo (1 unit/ml).

View larger version (137K):
[in a new window]
Fig. 4.
Differentiation of C2C12 cells.
A-C, C2C12 cells were cultured in growth medium for 48 h in the absence of Epo (A), presence of 1 unit/ml Epo
(B), and presence of 1 unit/ml Epo with anti-EpoR antibody
(C). D-F, C2C12 cells were cultured in
differentiation medium for 48 h in the absence of Epo
(D), presence of 1 unit/ml Epo (E), and presence
of 1 unit/ml Epo with anti-EpoR anti-EpoR antibody (F).
G-I, C2C12 cells were cultured in differentiation medium
for 120 h in the absence of Epo (G), presence of 1 unit/ml Epo (H), and presence of 1 unit/ml Epo with
anti-EpoR anti-EpoR antibody (I). J-M, to assess
myotube differentiation, C2C12 cells were cultured in
differentiation media without (J and L) and with
(K and M) Epo (1 unit/ml). Cells were fixed and
incubated with primary antibody against myosin heavy chain and stained
with a rhodamine-conjugated secondary antibody (L and
M).

View larger version (17K):
[in a new window]
Fig. 5.
Effect of Epo on
[Ca2+]c in C2C12 cells using
Fura-2 fluorescence. Undifferentiated C2C12 myoblasts
(A) and differentiated C2C12 myotubes (B) were
stimulated with Epo (10 units/ml) and carbachol (CCh, 100 µM). Calcium response after addition of Epo was inhibited
in undifferentiated C2C12 myoblasts in absence of extracellular calcium
(1-min preincubation in EGTA 3 mM) (C) or with 5 min pre-treatment with tyrphostin A51 (10 µM)
(D). Data are expressed as
[Ca2+]c (nM) after calibration.
The traces are representative of three to six similar experiments using
cells from different passages.

View larger version (31K):
[in a new window]
Fig. 6.
Epo stimulation of Jak2 and Stat5 tyrosine
phosphorylation. C2C12 whole cell extracts prepared from cells
untreated (lane 1) and treated with Epo
(lanes 2-5) at 5 units/ml with tyrphostin A51
(lane 3, 10
5
M; lane 4, 3 × 10
6 M; lane
5, 10
6 M) were
immunoprecipitated with anti-phosphotyrosine antibody and analyzed by
Western blot using antibodies specific for Jak2 and Stat5.

View larger version (24K):
[in a new window]
Fig. 7.
Expression analysis of EpoR and transcription
factors in C2C12 and satellite cells. A, C2C12 cells
were cultured in growth medium for 48 h followed by 48 and
120 h in differentiation medium in the absence and presence of Epo
(1 unit/ml). Expression of EpoR, Myf-5, MyoD, myogenin, and GATA-3 was
determined by RT-PCR. S16 analysis was included as a positive control.
M indicates the 100-bp ladder marker lane, and C
indicates the negative control. B-F, C2C12 cells cultured
in growth medium in the absence or presence of Epo (1 unit/ml)
(B-F) and for 48 h in culture in
differentiation medium in the absence and presence of Epo (1 unit/ml)
(F) were subjected to quantitative real-time RT-PCR
analysis. Results were normalized to S16. G, satellite cells
were cultured in differentiation medium in the absence and presence of
Epo (1 unit/ml) and subjected to quantitative real-time RT-PCR
analysis.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
) mice die presumably of severe anemia around
gestational day 13.5, the importance of Epo/EpoR in cardiac development
is indicated by the hypoplasia of ventricles of their heart prior to
death (19). No gross morphological limb changes have been observed in
EpoR (
/
) mice, and skeletal muscle defects in these mice have not
yet been identified.
(41). When Epo is removed from the medium, the cells
preserve their ability to differentiate. The proliferative response,
induction of Myf-5 and/or MyoD, and attenuation of the induction of
myogenin expression by Epo in differentiation medium raise the
possibility that Epo acts analogous to fibroblast growth factor and
transforming growth factor type
in altering the MyoD transcription
factor pattern during differentiation (41) and implicates regulation of
cyclin D1 expression (58).
| |
FOOTNOTES |
|---|
* This work was supported in part by the Swiss Foundation for Research on Muscular Diseases and the Association Française Contre les Myopathies.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Both authors contributed equally to this work.
To whom correspondence and reprint requests should be
addressed. Tel.: 301-496-1164; Fax: 301-402-0101; E-mail:
cnoguchi@helix.nih.gov.
** Supported by Grant 3100-56877.99 from the Swiss National Science Foundation.
Published, JBC Papers in Press, September 19, 2000, DOI 10.1074/jbc.M004999200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: Epo, erythropoietin; EpoR, erythropoietin receptor; FBS, fetal bovine serum; RT, reverse transcription; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; bp, base pair(s); PSS, physiological salt solution; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Wu, H., Klingmuller, U., Besmer, P., and Lodish, H. F. (1995) Nature 377 (6546), 242-246 |
| 2. | Watowich, S. S., Liu, K. D., Xie, X., Lai, S. Y., Mikami, A., Longmore, G. D., and Goldsmith, M. A. (1999) J. Biol. Chem. 274, 5415-5421 |
| 3. | Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Cell 93, 397-409 |
| 4. | Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 385-395 |
| 5. | Quelle, F. W., Wang, D., Nosaka, T., Thierfelder, W. E., Stravopodis, D., Weinstein, Y., and Ihle, J. N. (1996) Mol. Cell. Biol. 16, 1622-1631 |
| 6. | Sawyer, S. T., and Penta, K. (1996) J. Biol. Chem. 271, 32430-32437 |
| 7. | Miller, B. A., Barber, D. L., Bell, L. L., Beattie, B. K., Zhang, M. Y., Neel, B. G., Yoakim, M., Rothblum, L. I., and Cheung, J. Y. (1999) J. Biol. Chem. 274, 20465-20472 |
| 8. | Socolovsky, M., Fallon, A. E., and Lodish, H. F. (1998) Blood 92, 1491-1496 |
| 9. | Muta, K., Krantz, S. B., Bondurant, M. C., and Wickrema, A. (1994) J. Clin. Invest. 94, 34-43 |
| 10. | Gregory, T., Yu, C., Ma, A., Orkin, S. H., Blobel, G. A., and Weiss, M. J. (1999) Blood 94, 87-96 |
| 11. | Socolovsky, M., Dusanter-Fourt, I., and Lodish, H. F. (1997) J. Biol. Chem. 272, 14009-14012 |
| 12. | Orlic, D., Anderson, S., Biesecker, L. G., Sorrentino, B. P., and Bodine, D. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4601-4605 |
| 13. | Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E. S., Kessimian, N., and Noguchi, C. T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3974-3978 |
| 14. | Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell'Era, P., Nico, B., Roncali, L., and Dammacco, F. (1999) Blood 93, 2627-2636 |
| 15. | Sakanaka, M., Wen, T. C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., and Sasaki, R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4635-4640 |
| 16. | Yasuda, Y., Masuda, S., Chikuma, M., Inoue, K., Nagao, M., and Sasaki, R. (1998) J. Biol. Chem. 273, 25381-25387 |
| 17. | Marrero, M. B., Venema, R. C., Ma, H., Ling, B. N., and Eaton, D. C. (1998) Kidney Int. 53, 1259-1268 |
| 18. | Zaman, K., Ryu, H., Hall, D., O'Donovan, K., Lin, K. I., Miller, M. P., Marquis, J. C., Baraban, J. M., Semenza, G. L., and Ratan, R. R. (1999) J. Neurosci. 19, 9821-9830 |
| 19. | Wu, H., Lee, S. H., Gao, J., Liu, X., and Iruela-Arispe, M. L. (1999) Development 126, 3597-3605 |
| 20. | Liu, Z.-Y., Chin, K., and Noguchi, C. T. (1994) Dev. Biol. 166, 159-169 |
| 21. | Liu, C., Shen, K., Liu, Z., and Noguchi, C. T. (1997) J. Biol. Chem. 272, 32395-32400 |
| 22. | Papayannopoulou, T., Nakamoto, B., Kurachi, S., Tweeddale, M., and Messner, H. (1988) Blood 72, 1029-1038 |
| 23. | Yaffe, D., and Saxel, O. (1977) Nature 270, 725-727 |
| 24. | Blau, H. M., Pavlath, G. K., Hardeman, E. C., Chiu, C. P., Silberstein, L., Webster, S. G., Miller, S. C., and Webster, C. (1985) Science 230, 758-766 |
| 25. | Blau, H. M., and Webster, C. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 5623-5627 |
| 26. | Bader, D., Masaki, T., and Fischman, D. A. (1982) J. Cell Biol. 95, 763-770 |
| 27. | Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450 |
| 28. | Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E., and Rudnicki, M. A. (1996) Genes Dev. 10, 1173-1183 |
| 29. | Blaveri, K., Heslop, L., Yu, D. S., Rosenblatt, J. D., Gross, J. G., Partridge, T. A., and Morgan, J. E. (1999) Dev. Dyn. 216, 244-256 |
| 30. | Fibach, E., Schechter, A. N., Noguchi, C. T., and Rodgers, G. P. (1994) Br. J. Haematol. 88, 38-45 |
| 31. | Miller, B. A., Cheung, J. Y., Tillotson, D. L., Hope, S. M., and Scaduto, R. C. J. (1989) Blood 73 (5), 1188-1194 |
| 32. | Levitzki, A., and Gazit, A. (1995) Science 267, 1782-1788 |
| 33. | Noguchi, C. T., Bae, K. S., Chin, K., Wada, Y., Schechter, A. N., and Hankins, W. D. (1991) Blood 78, 2548-2556 |
| 34. | Chin, K., Oda, N., Shen, K., and Noguchi, C. T. (1995) Nucleic Acids Res. 23, 3041-3049 |
| 35. | Wu, H., Liu, X., Jaenisch, R., and Lodish, H. F. (1995) Cell 83, 59-67 |
| 36. | Anagnostou, A., Lee, E. S., Kessimian, N., Levinson, R., and Steiner, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5978-5982 |
| 37. | Masuda, S., Nagao, M., Takahata, K., Konishi, Y., Gallyas, F., Jr., Tabira, T., and Sasaki, R. (1993) J. Biol. Chem. 268, 11208-11216 |
| 38. | Jacobs-Helber, S. M., Wickrema, A., Birrer, M. J., and Sawyer, S. T. (1998) Mol. Cell. Biol. 18, 3699-3707 |
| 39. | Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., and Mulligan, R. C. (1999) Nature 401, 390-394 |
| 40. | Olson, E. N., Brennan, T. J., Chakraborty, T., Cheng, T. C., Cserjesi, P., Edmondson, D., James, G., and Li, L. (1991) Mol. Cell. Biochem. 104, 7-13 |
| 41. | Olson, E. N. (1992) Dev. Biol. 154, 261-272 |
| 42. | Broudy, V. C., Lin, N., Brice, M., Nakamoto, B., and Papayannopoulou, T. (1991) Blood 77, 2583-2590 |
| 43. | Fairbairn, L. J., Cowling, G. J., Reipert, B. M., and Dexter, T. M. (1993) Cell 74, 823-832 |
| 44. | Fukunaga, R., Ishizaka-Ikeda, E., and Nagata, S. (1993) Cell 74, 1079-1087 |
| 45. | Socolovsky, M., Lodish, H. F., and Daley, G. Q. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6573-6575 |
| 46. | Stockdale, F. E. (1992) Dev. Biol. 154, 284-298 |
| 47. | Kimata, H., Yoshida, A., Ishioka, C., Masuda, S., R., S., and Mikawa, H. (1991) Clin. Exp. Immunol. 85, 151-156 |
| 48. | Ohneda, O., Yanai, N., and Obinata, M. (1993) Exp. Cell. Res. 208, 327-331 |
| 49. | Konishi, Y., Chui, D.-H., Hirose, H., Kunishita, T., and Tabira, T. (1993) Brain Res. 609, 29-35 |
| 50. | Wald, M. R., Borda, E. S., and Sterin-Borda, L. (1996) J. Cell. Physiol. 167, 461-468 |
| 51. | Cheung, J. Y., Zhang, X.-Q., Bokvist, K., Tillotson, D. L., and Miller, B. A. (1997) Blood 89, 92-100 |
| 52. | Miller, B. A., and Cheung, J. Y. (1994) Proc. Soc. Exp. Biol. Med. 206, 263-267 |
| 53. | Vogel, V., Kramer, H. J., Bäcker, A., Meyer-Lehnert, H., Jelkmann, W., and Fandrey, J. (1997) Am. J. Hypertens. 10, 289-296 |
| 54. | Morakkabati, N., Gollnick, F., Meyer, R., Fandrey, J., and Jelkmann, W. (1996) Exp. Hematol. 24, 392-397 |
| 55. | Olson, E. N. (1990) Genes Dev. 4, 1454-1461 |
| 56. | Molkentin, J. D., and Olson, E. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9366-9373 |
| 57. | Wright, W. E., Sassoon, D. A., and Lin, V. K. (1989) Cell 56, 607-617 |
| 58. | Rao, S. S., Chu, C., and Kohtz, D. S. (1994) Mol. Cell. Biol. 14, 5259-5267 |
| 59. | Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G., and Mavilio, F. (1998) Science 279, 1528-1530 |
| 60. | Jackson, K. A., Mi, T., and Goodell, M. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14482-14486 |
This article has been cited by other articles:
![]() |
Q. Tong, I. Hirschler-Laszkiewicz, W. Zhang, K. Conrad, D. W. Neagley, D. L. Barber, J. Y. Cheung, and B. A. Miller TRPC3 Is the Erythropoietin-regulated Calcium Channel in Human Erythroid Cells J. Biol. Chem., April 18, 2008; 283(16): 10385 - 10395. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Y. Chen, P. Asavaritikrai, J. T. Prchal, and C. T. Noguchi Endogenous Erythropoietin Signaling Is Required for Normal Neural Progenitor Cell Proliferation J. Biol. Chem., August 31, 2007; 282(35): 25875 - 25883. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. LeBaron, T. J. Ahonen, M. T. Nevalainen, and H. Rui In Vivo Response-Based Identification of Direct Hormone Target Cell Populations Using High-Density Tissue Arrays Endocrinology, March 1, 2007; 148(3): 989 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schneider, K. Jaquet, R. Malisius, S. Geidel, E. Bahlmann, S. Boczor, T. Rau, M. Antz, K.-H. Kuck, and K. Krause Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium Eur. Heart J., February 2, 2007; 28(4): 499 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Dunlop, A. P. Maxwell, and T. R.J. Lappin Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma Stem Cells, February 1, 2007; 25(2): 380 - 384. [Abstract] [Full Text] [PDF] |